AVM Biotechnology, Inc.
Seattle, WA Doing business as AVM Biotechnology LLC
- UEI
- D29NFMS3DJJ8
- CAGE
- 59W32
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 8226 23rd Ave NE, Seattle, WA 98115, USA
- Website
- avmbiotech.com
- Founded
- 2008
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Immunomodulatory AVM0703 to bridge relapsed/refractory diffuse large b-cell lymphoma patients to car-t cell… | National Cancer Institute | $992,425 | |
| AVM0703 combined with non-hodgkin's lymphoma standard of care to enhance complete response rates without additional… | National Cancer Institute | $798,386 | |
| Expedited expansion cohort clinical trial for relapsed/refractory 'no-option' non-hodgkin's lymphoma/leukemia patients -… | National Cancer Institute | $2,999,997 | |
| A novel non-toxic preconditioning regimen for cancer cell therapy | National Cancer Institute | $224,770 | |
| Targeted lymphoablation as an alternative to hsct to cure T1D - project summary with insulin being the only approved… | National Institute of Diabetes and Digestive and Kidney Diseases | $4,598,094 |
About AVM Biotechnology, Inc.
AVM Biotechnology, Inc., registered in SAM.gov since 2008, is a woman-owned small business located in Seattle, Washington, focused on developing innovative immunomodulatory therapies for cancer treatment. The company specializes in developing proprietary pharmaceutical formulations, with a particular focus on addressing challenges in Non-Hodgkin's Lymphoma (NHL) treatment, specifically targeting diffuse large B-cell lymphoma (DLBCL). As a for-profit corporate entity, AVM Biotechnology has established itself as a promising biotechnology firm with a concentrated research and development approach in oncological therapeutics.
The company has secured multiple federal grant awards from the National Cancer Institute (NCI) under the Cancer Treatment Research program, focusing on developing AVM0703, a proprietary high-concentration dexamethasone sodium phosphate formulation designed to bridge treatment gaps for relapsed/refractory NHL patients. Their grant-funded projects aim to enhance cancer treatment strategies, including developing immunomodulatory therapies to stabilize tumor burden, improve patient outcomes, and provide alternatives for patients unable to immediately access chimeric antigen receptor T-cell (CAR-T) immunotherapy. The clinical research spans multiple institutional partners, including City of Hope, UCLA, Norton Cancer Institute, Levine Cancer Institute, and University of Texas Southwestern, with ongoing FDA-approved clinical trials exploring AVM0703's potential in treating lymphoid malignancies. The grants, ranging from $992,425 to support various research phases, demonstrate the company's commitment to advancing cancer treatment options for patients with limited therapeutic alternatives.
Quick answers
What is AVM Biotechnology, Inc.'s UEI?
AVM Biotechnology, Inc.'s Unique Entity ID (UEI) in SAM.gov is D29NFMS3DJJ8.
What is AVM Biotechnology, Inc.'s CAGE code?
AVM Biotechnology, Inc.'s CAGE code is 59W32.
Where is AVM Biotechnology, Inc. located?
AVM Biotechnology, Inc.'s physical address in SAM.gov is 8226 23rd Ave NE, Seattle, WA 98115, USA.
Is AVM Biotechnology, Inc. registered in SAM.gov?
Yes. AVM Biotechnology, Inc.'s SAM.gov registration is active through March 3, 2027.
What is AVM Biotechnology, Inc.'s most recent federal award?
AVM Biotechnology, Inc.'s most recent federal grant award is Immunomodulatory AVM0703 to bridge relapsed/refractory diffuse large b-cell lymphoma patients to car-t cell… (R44CA310370), from National Cancer Institute, on September 8, 2025.
On GovTribe
See AVM Biotechnology, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors